What’s Next For FDA In Face Of Opposing Mifepristone Injunctions
Executive Summary
Agency appeals Texas federal court decision staying its approval of the medication abortion pill. It is unclear how the ruling would be implemented if it stands, and what the impact might be from an opposing same-day order from another court for FDA to keep mifepristone available. Texas ruling could have significant consequences for industry, former FDA attorney says.
You may also be interested in...
Supreme Court Could Curtail Mifepristone Access, Lay Out ‘Road Map’ To Challenge FDA Approvals
Court decision on whether an anti-abortion group has standing to challenge FDA actions could dispose of case or open door to similar suits. Ruling will determine if pre-2016 REMS restrictions are reinstated.
Generic And Branded Mifepristone Remain On US Market Following Supreme Court Stay
GenBioPro will be able to continue selling its generic mifepristone, after the Supreme Court overruled a stay from the Fifth Circuit which could have seen generic approval rescinded and significant restrictions placed on the drug’s use.
GenBioPro Suit Against FDA May Preserve Generic Mifepristone Approval
GenBioPro has filed a lawsuit against the FDA to try and preserve the approval of its generic mifepristone product, should the Supreme Court allow an order from a Texas judge to overrule the Food and Drug Administration’s approval of the drug.